169 related articles for article (PubMed ID: 38593584)
1. Stroma AReactive Invasion Front Areas (SARIFA): a novel histopathologic biomarker in colorectal cancer patients and its association with the luminal tumour proportion.
Reitsam NG; Grosser B; Enke JS; Mueller W; Westwood A; West NP; Quirke P; Märkl B; Grabsch HI
Transl Oncol; 2024 Jun; 44():101913. PubMed ID: 38593584
[TBL] [Abstract][Full Text] [Related]
2. Stroma AReactive Invasion Front Areas (SARIFA) predict poor survival in adenocarcinomas of the stomach and gastrooesophageal junction: a validation study.
Ulase D; Behrens HM; Röcken C
Virchows Arch; 2024 May; ():. PubMed ID: 38748262
[TBL] [Abstract][Full Text] [Related]
3. Stroma AReactive Invasion Front Areas (SARIFA)-A New Easily to Determine Biomarker in Colon Cancer-Results of a Retrospective Study.
Martin B; Grosser B; Kempkens L; Miller S; Bauer S; Dhillon C; Banner BM; Brendel EM; Sipos É; Vlasenko D; Schenkirsch G; Schiele S; Müller G; Märkl B
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638364
[TBL] [Abstract][Full Text] [Related]
4. Alterations in Natural Killer Cells in Colorectal Cancer Patients with Stroma AReactive Invasion Front Areas (SARIFA).
Reitsam NG; Märkl B; Dintner S; Sipos E; Grochowski P; Grosser B; Sommer F; Eser S; Nerlinger P; Jordan F; Rank A; Löhr P; Waidhauser J
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765951
[TBL] [Abstract][Full Text] [Related]
5. SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer.
Enke JS; Groß M; Grosser B; Sipos E; Steinestel J; Löhr P; Waidhauser J; Lapa C; Märkl B; Reitsam NG
BMC Cancer; 2024 Jan; 24(1):65. PubMed ID: 38216952
[TBL] [Abstract][Full Text] [Related]
6. Stroma AReactive Invasion Front Areas (SARIFA) - a new prognostic biomarker in gastric cancer related to tumor-promoting adipocytes.
Grosser B; Glückstein MI; Dhillon C; Schiele S; Dintner S; VanSchoiack A; Kroeppler D; Martin B; Probst A; Vlasenko D; Schenkirsch G; Märkl B
J Pathol; 2022 Jan; 256(1):71-82. PubMed ID: 34580877
[TBL] [Abstract][Full Text] [Related]
7. Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial.
Grosser B; Emmerson J; Reitsam NG; Cunningham D; Nankivell M; Langley RE; Allum WH; Trepel M; Märkl B; Grabsch HI
Br J Cancer; 2024 Feb; 130(3):457-466. PubMed ID: 38123705
[TBL] [Abstract][Full Text] [Related]
8. Novel biomarker SARIFA in colorectal cancer: highly prognostic, not genetically driven and histologic indicator of a distinct tumor biology.
Reitsam NG; Grozdanov V; Löffler CML; Muti HS; Grosser B; Kather JN; Märkl B
Cancer Gene Ther; 2024 Feb; 31(2):207-216. PubMed ID: 37990064
[TBL] [Abstract][Full Text] [Related]
9. Stroma AReactive Invasion Front Areas (SARIFA) proves prognostic relevance in gastric carcinoma and is based on a tumor-adipocyte interaction indicating an altered immune response.
Grosser B; Heyer CM; Austgen J; Sipos E; Reitsam NG; Hauser A; VanSchoiack A; Kroeppler D; Vlasenko D; Probst A; Novotny A; Weichert W; Keller G; Schlesner M; Märkl B
Gastric Cancer; 2024 Jan; 27(1):72-85. PubMed ID: 37874427
[TBL] [Abstract][Full Text] [Related]
10. Combined Features Based on Preoperative Controlling Nutritional Status Score and Circulating Tumour Cell Status Predict Prognosis for Colorectal Cancer Patients Treated with Curative Resection.
Yang C; Wei C; Wang S; Han S; Shi D; Zhang C; Lin X; Dou R; Xiong B
Int J Biol Sci; 2019; 15(6):1325-1335. PubMed ID: 31223290
[No Abstract] [Full Text] [Related]
11. Desmoplastic Reaction Associates with Prognosis and Adjuvant Chemotherapy Response in Colorectal Cancer: A Multicenter Retrospective Study.
Hu Q; Wang Y; Yao S; Mao Y; Liu L; Li Z; Chen Y; Zhang S; Li Q; Zhao Y; Fan X; Cui Y; Zhao K; Liu Z
Cancer Res Commun; 2023 Jun; 3(6):1057-1066. PubMed ID: 37377615
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study.
Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF
Int J Colorectal Dis; 2018 Aug; 33(8):1115-1124. PubMed ID: 29785462
[TBL] [Abstract][Full Text] [Related]
13. Tumour-stroma ratio has poor prognostic value in nonpedunculated T1 colorectal cancer: A multicentre case-cohort study.
Dang H; van Pelt GW; Haasnoot KJC; Backes Y; Elias SG; Seerden TCJ; Schwartz MP; Spanier BWM; de Vos Tot Nederveen Cappel WH; van Bergeijk JD; Kessels K; Geesing JMJ; Groen JN; Borg FT; Wolfhagen FHJ; Seldenrijk CA; Raicu MG; Milne AN; van Lent AUG; Brosens LAA; Johan A Offerhaus G; Siersema PD; Tollenaar RAEM; Hardwick JCH; Hawinkels LJAC; Moons LMG; Lacle MM; Mesker WE; Boonstra JJ;
United European Gastroenterol J; 2021 Feb; ():. PubMed ID: 33566452
[TBL] [Abstract][Full Text] [Related]
14. Relationship between the Warburg effect in tumour cells and the tumour microenvironment in colorectal cancer patients: Results from a large multicentre study.
Steeghs JPJM; Offermans K; Jenniskens JCA; Samarska I; Fazzi GE; van den Brandt PA; Grabsch HI
Pathol Res Pract; 2023 Jul; 247():154518. PubMed ID: 37209573
[TBL] [Abstract][Full Text] [Related]
15. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer.
Park JH; Richards CH; McMillan DC; Horgan PG; Roxburgh CSD
Ann Oncol; 2014 Mar; 25(3):644-651. PubMed ID: 24458470
[TBL] [Abstract][Full Text] [Related]
16. Peritumoral tertiary lymphoid structure and tumor stroma percentage predict the prognosis of patients with non-metastatic colorectal cancer.
Wang Q; Shen X; An R; Bai J; Dong J; Cai H; Zhu H; Zhong W; Chen W; Liu A; Du J
Front Immunol; 2022; 13():962056. PubMed ID: 36189233
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of desmoplastic stromal reaction, tumor budding and tumor-stroma ratio in stage II colorectal cancer.
Fan S; Cui X; Zheng L; Ma W; Zheng S; Wang J; Qi L; Ye Z
J Gastrointest Oncol; 2022 Dec; 13(6):2903-2921. PubMed ID: 36636094
[TBL] [Abstract][Full Text] [Related]
18. Intraepithelial tumour infiltrating lymphocytes are associated with absence of tumour budding and immature/myxoid desmoplastic reaction, and with better recurrence-free survival in stages I-III colorectal cancer.
González IA; Bauer PS; Liu J; Chatterjee D
Histopathology; 2021 Jan; 78(2):252-264. PubMed ID: 32654226
[TBL] [Abstract][Full Text] [Related]
19. Tumour-stroma ratio has poor prognostic value in non-pedunculated T1 colorectal cancer: A multi-centre case-cohort study.
Dang H; van Pelt GW; Haasnoot KJ; Backes Y; Elias SG; Seerden TC; Schwartz MP; Spanier BW; de Vos Tot Nederveen Cappel WH; van Bergeijk JD; Kessels K; Geesing JM; Groen JN; Ter Borg F; Wolfhagen FH; Seldenrijk CA; Raicu MG; Milne AN; van Lent AU; Brosens LA; Offerhaus GJA; Siersema PD; Tollenaar RA; Hardwick JC; Hawinkels LJ; Moons LM; Lacle MM; Mesker WE; Boonstra JJ;
United European Gastroenterol J; 2020 Nov; 9(4):2050640620975324. PubMed ID: 33210982
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer.
Sandberg TP; Stuart MPME; Oosting J; Tollenaar RAEM; Sier CFM; Mesker WE
BMC Cancer; 2019 Mar; 19(1):284. PubMed ID: 30922247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
